FDA Clears First Gene Therapy to Restore Hearing to Normal Levels

Regeneron Pharmaceuticals has secured FDA accelerated approval for Otarmeni (lunsotogene parvec-cwha), an AAV vector-based gene therapy for severe-to-profound sensorineural hearing loss caused by biallelic OTOF gene variants. The approval marks the first time a gene therapy has demonstrated restoration of neurosensory function to normal levels in a clinical setting, and the first gene therapy cleared under the FDA Commissioner's National Priority Voucher program. For QA and regulatory teams tracking accelerated approval pathways and emerging voucher frameworks, this decision establishes a precedent with broad implications for how ultra-rare neurosensory indications are reviewed and confirmed.

Approval was granted on the basis of hearing sensitivity improvement measured by average pure tone audiometry at week 24 in the CHORD trial. Eighty percent of participants achieved or surpassed the primary endpoint hearing level, and with longer follow-up, 42% achieved normal hearing inclusive of whisper detection. Continued approval remains contingent on verification of clinical benefit in the confirmatory portion of CHORD. The indicated population is pediatric and adult patients with PTA thresholds exceeding 90 dB HL at any frequency, molecularly confirmed biallelic OTOF variants, preserved outer hair cell function, and no prior cochlear implant in the treated ear. Otarmeni is contraindicated where preoperative imaging indicates inner ear access is not feasible, including cases involving abnormal mastoid pneumatization or clinically significant anatomic variations.

OTOF-related hearing loss affects approximately 50 newborns per year in the U.S., classifying it as ultra-rare. The condition results from absence of functional otoferlin protein, which mediates signaling between inner ear sensory cells and the auditory nerve, despite structurally intact ear anatomy. Prior to this approval, management was limited to lifelong device-based interventions. Regeneron has stated it will provide Otarmeni at no cost to U.S. patients, a distribution model that will require close coordination between specialty pharmacy, site-of-care administration teams, and payer infrastructure.

CHORD trial investigator A. Eliot Shearer, M.D., Ph.D., of Boston Children's Hospital and Harvard Medical School, noted that the therapy produced rapid, consistent hearing responses in pediatric participants. Regeneron's Chief Scientific Officer George D. Yancopoulos, M.D., Ph.D., described Otarmeni as the company's first approved genetic medicine. Manufacturing and quality teams should note that as an in vivo AAV-based therapy administered via cochlear delivery, Otarmeni will present distinct sterility assurance, process validation, and cold-chain requirements compared to systemic gene therapy platforms.